The U.S. Food and Drug Administration (FDA) is warning the public about "adverse events" associated with some "permanent" makeup treatments.
FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum
The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma
What’s New in Pediatric Dermatology With Elizabeth (Lisa) Swanson, MD
The Cutaneous Connection: Episode 7- Tips and Tricks for Treating Young Skin of Color Patients
Non-Invasive Test That May Help Predict Eczema in Babies
Treatment of Plaque Psoriasis in Children
2 Clarke Drive Cranbury, NJ 08512